Deutsche Bank AG Analysts Give Novartis AG (NOVN) a CHF 83.50 Price Target
Novartis AG (VTX:NOVN) received a CHF 83.50 price target from investment analysts at Deutsche Bank AG in a research report issued to clients and investors on Wednesday. The brokerage presently has a “neutral” rating on the stock.
NOVN has been the subject of a number of other research reports. S&P Global set a CHF 82 price objective on shares of Novartis AG and gave the company a “neutral” rating in a research report on Tuesday, July 18th. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on shares of Novartis AG and gave the company a “neutral” rating in a report on Thursday, July 20th. Barclays PLC set a CHF 80 target price on shares of Novartis AG and gave the company a “neutral” rating in a report on Friday, June 23rd. Jefferies Group LLC set a CHF 103 target price on shares of Novartis AG and gave the company a “buy” rating in a research note on Friday, June 23rd. Finally, Morgan Stanley set a CHF 88 target price on shares of Novartis AG and gave the company a “buy” rating in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of CHF 85.17.
Shares of Novartis AG (VTX:NOVN) opened at 84.15 on Wednesday. The company’s 50-day moving average price is CHK 81.61 and its 200 day moving average price is CHK 79.17. The company has a market cap of CHK 197.15 billion and a P/E ratio of 30.72. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 84.60.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/deutsche-bank-ag-analysts-give-novartis-ag-novn-a-chf-83-50-price-target.html.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.